法兰德斯画家鲁本斯笔下的田园景致 | Peter Paul Rubens | 巴洛克画派 epochtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from epochtimes.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Quotient Limited Participate in the BTIG Virtual MedTech, Digital Health, Life Science & .
Quotient LimitedFebruary 12, 2021 GMT
JERSEY, Channel Islands, Feb. 12, 2021 (GLOBE NEWSWIRE) Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today announced the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Thursday, February 18.
About Quotient Limited
Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different moda
Quotient Limited Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 12, 2021 09:00 ET | Source: Quotient Limited Quotient Limited Newtown, Pennsylvania, UNITED STATES
JERSEY, Channel Islands, Feb. 12, 2021 (GLOBE NEWSWIRE) Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today announced the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Thursday, February 18.
About Quotient Limited
Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platfo
Quotient Limited Reports Third Quarter Fiscal 2021 Results and Business Update
Nachrichtenquelle: globenewswire | 01.02.2021, 12:00 | 130
Expanded MosaiQ IH microarray EU launch planned for fourth quarter CY2021
Sales of Alba by Quotient reagents exceed guidance
Strong cash position in place to carry us into commercialization JERSEY, Channel Islands, Feb. 01, 2021 (GLOBE NEWSWIRE) Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its third quarter fiscal 2021 results and other notable developments. Notable developments include the CE marking of the Company s MosaiQ semi-quantitative COVID-19 antibody test, which is an enhanced version of the Company s previously approved COVID antibody test.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Quotient Limited Provides Status Update on the Initial SDS Microarray and MosaiQ Instrument for .
Quotient LimitedDecember 10, 2020 GMT
JERSEY, Channel Islands, Dec. 10, 2020 (GLOBE NEWSWIRE) Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that it received a request from the U.S. Food and Drug Administration (FDA) for additional testing data regarding the 510(k) application for the Initial Serological Disease Screening Microarray (SDS) and MosaiQ instrument. The data the FDA has requested relates to specific individual performance characteristics of the assays on the microarray. In response to this request, the Company intends to re-submit its application, with the additional data requested by the FDA, in early 2021. Following that submission, the Company is targeting to receive the FDA 510(k) clearance in mid-2021.